What Is Heron Therapeutics, Inc. (HRTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Heron Therapeutics, Inc.'s intrinsic value is estimated at $0.74, suggesting a +69.0% average upside from the current price of $0.44. While 8 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: First Chicago targets $1.31 (+199.4%), versus Bayesian DCF at $0.14 (-68.2%). This +267.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About HRTX?
11 of 13 models are currently active for HRTX. Of these, 8 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates HRTX's intrinsic value at $0.14, implying -68.2% downside from the current price. See which stocks rank higher →
How Does HRTX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, HRTX ranks #120 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Heron Therapeutics, Inc., metrics like R&D productivity ratio provide important context that general-purpose valuation models may underweight.
Is HRTX a Value Trap?
CirclFi's Value Trap algorithm assigns HRTX a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Heron Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Heron Therapeutics, Inc. scores 6.1 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +267.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every HRTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across HRTX's 11 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad